L9LS in Women of Childbearing Potential in Mali

PHASE2RecruitingINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Malaria
Interventions
BIOLOGICAL

Single dose of 1800 mg L9LS SC

A human monoclonal antibody to protect against Plasmodium falciparum.

OTHER

Placebo

Normal saline

Trial Locations (3)

Unknown

RECRUITING

Faladje MRTC Clinic, Faladié

RECRUITING

Kalifabougou MRTC Clinic, Kalifabougou

RECRUITING

Torodo MRTC Clinic, Torodo

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

University of the Sciences, Techniques and Technologies of Bamako

OTHER

collaborator

Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS)

UNKNOWN

collaborator

University of Washington

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

Indiana University School of Medicine

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT07060508 - L9LS in Women of Childbearing Potential in Mali | Biotech Hunter | Biotech Hunter